Eliquis

Deep Vein Thrombosis, Arthroplasty, Pulmonary Embolism + 8 more

Treatment

16 FDA approvals

20 Active Studies for Eliquis

What is Eliquis

Apixaban

The Generic name of this drug

Treatment Summary

Apixaban is an oral medication used to prevent and treat blood clots. It works by targeting a protein called Factor Xa which plays a role in blood clotting. Apixaban is sold under the brand name Eliquis and was approved by the FDA in 2012.

Eliquis

is the brand name

image of different drug pills on a surface

Eliquis Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Eliquis

Apixaban

2012

15

Approved as Treatment by the FDA

Apixaban, otherwise known as Eliquis, is approved by the FDA for 16 uses which include Deep Vein Thrombosis and Prophylaxis of Deep Vein Thrombosis .

Deep Vein Thrombosis

Prophylaxis of Deep Vein Thrombosis

Deep vein thrombosis recurrent

Non Valvular Atrial Fibrillation (nv AF)

Recurrent Pulmonary Embolism (Disorder)

Arthroplasty

recurrent Prophylaxis of Deep Vein Thrombosis

Deep Vein Thrombosis

Total Knee Arthroplasty

Stroke

Atrial Fibrillation

Systemic Embolism

Pulmonary Embolism

Disease

Pulmonary Embolism

Deep Vein Thrombosis

Effectiveness

How Eliquis Affects Patients

Apixaban works by blocking the clotting proteins factor Xa and prothrominase, preventing them from forming blood clots.

How Eliquis works in the body

Apixaban stops the formation of blood clots by inhibiting the activity of a certain type of blood protein called factor Xa. It also blocks prothrominase, which helps to prevent the formation of a clot.

When to interrupt dosage

The proposed dosage of Eliquis is contingent upon the indicated condition, including Deep Vein Thrombosis (DVT), Deep Vein Thrombosis and Arthroplasty. The amount of dosage varies, depending on the technique of delivery (e.g. Oral or Tablet, film coated - Oral) featured in the table beneath.

Condition

Dosage

Administration

Deep Vein Thrombosis

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Pulmonary Embolism

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Atrial Fibrillation

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Disease

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Deep Vein Thrombosis

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Stroke

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

recurrent Prophylaxis of Deep Vein Thrombosis

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Total Knee Arthroplasty

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Systemic Embolism

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Arthroplasty

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Pulmonary Embolism

, 2.5 mg, 5.0 mg, 10.0 mg

Oral, Tablet, Tablet - Oral, , Tablet, film coated - Oral, Tablet, film coated

Warnings

Eliquis Contraindications

Condition

Risk Level

Notes

Hemorrhage

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Apixaban may interact with Pulse Frequency

There are 20 known major drug interactions with Eliquis.

Common Eliquis Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

Apixaban may increase the anticoagulant activities of (R)-warfarin.

(S)-Warfarin

Major

Apixaban may increase the anticoagulant activities of (S)-Warfarin.

4-hydroxycoumarin

Major

Apixaban may increase the anticoagulant activities of 4-hydroxycoumarin.

Abciximab

Major

Apixaban may increase the anticoagulant activities of Abciximab.

Acenocoumarol

Major

Apixaban may increase the anticoagulant activities of Acenocoumarol.

Eliquis Toxicity & Overdose Risk

Animal studies suggest that apixaban may increase a mother's risk of bleeding during pregnancy, but it is unknown if this is true for humans. Therefore, apixaban should only be used if the benefits outweigh the risks. It is not known if apixaban is safe and effective during labor and delivery, but animal studies suggest an increased rate of maternal bleeding. It is not known if apixaban is excreted in human milk, but animal studies have shown that it is excreted in rat milk. Nursing mothers should discuss the risks and benefits of either stopping breastfeeding or taking apixaban. Apixaban has not been

image of a doctor in a lab doing drug, clinical research

Eliquis Novel Uses: Which Conditions Have a Clinical Trial Featuring Eliquis?

83 active trials are presently being conducted to assess the potential of Eliquis for alleviating Deep Vein Thrombosis (DVT), Stroke and Pulmonary Embolism.

Condition

Clinical Trials

Trial Phases

Pulmonary Embolism

22 Actively Recruiting

Early Phase 1, Phase 4, Phase 3, Not Applicable

Total Knee Arthroplasty

6 Actively Recruiting

Not Applicable, Phase 2, Phase 3

recurrent Prophylaxis of Deep Vein Thrombosis

0 Actively Recruiting

Atrial Fibrillation

2 Actively Recruiting

Not Applicable

Deep Vein Thrombosis

0 Actively Recruiting

Deep Vein Thrombosis

9 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 4

Disease

0 Actively Recruiting

Arthroplasty

3 Actively Recruiting

Not Applicable

Stroke

6 Actively Recruiting

Not Applicable, Phase 1

Pulmonary Embolism

0 Actively Recruiting

Systemic Embolism

2 Actively Recruiting

Not Applicable

Eliquis Reviews: What are patients saying about Eliquis?

5

Patient Review

7/25/2022

Eliquis for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

I haven't experienced any negative side effects and I really feel like it's kept me alive. The only downside is that it's quite expensive.

4

Patient Review

1/3/2022

Eliquis for Deep Vein Thrombosis Prevention

I'm a 47-year-old firefighter who has a history of atrial fibrillation and deep vein thrombosis. My doctor put me on this medication 3 weeks ago to prevent another clotting episode, and while I have noticed that I'm more tired than usual and having trouble focusing, I would rather deal with these issues than suffer from a stroke or another DVT.

4

Patient Review

5/11/2021

Eliquis for Blood Clot in Lung

I've been on Eliquis for four months to treat a pulmonary embolism. I'm grateful that the medication has helped dissolve the blood clot, but the side effects have been really tough to deal with. Headaches, shortness of breath, chest pain, and joint pain have all made it difficult to get through my day-to-day.

4

Patient Review

5/22/2021

Eliquis for Treatment to Prevent Recurrence of a Clot in a Deep Vein

I just started this treatment and I haven't experienced any side effects yet. My upset stomach could be from not eating, but I'm on it for DVT so that might also be a factor. I'll give more information if anything else comes up.

4

Patient Review

10/7/2022

Eliquis for Treatment to Prevent Recurrence of a Clot in a Deep Vein

I've been on this medication for a few years now due to congestive heart failure and several blockages. Recently, I also started having problems with bladder bleeding, as well as on my arms and legs. I've decided to stop taking the medication and take my chances; it's my choice and my life.

3.7

Patient Review

5/4/2021

Eliquis for Blood Clot in a Deep Vein

It's alright.

3

Patient Review

1/9/2022

Eliquis for Treatment to Prevent a Blood Clot in the Lung

I'm a 58 year old male who's been taking Apixaban for two months now. I haven't noticed any side effects, but I have noticed that when I do get cuts, they don't seem to bleed as much. I'll have to mention this to my doctor next time I see him.

2.7

Patient Review

6/29/2022

Eliquis for Deep Vein Thrombosis Prevention

I'm a recent user so I can't speak to its long-term effectiveness yet. So far, however, I've had some difficulty with word-finding and increased fatigue. Additionally, I began feeling dizzy a few days ago which is concerning. Overall, though, it hasn't been too bad and I'll be discussing these effects with my primary care physician tomorrow and cardiologist next week.

2.7

Patient Review

5/7/2022

Eliquis for Treatment to Prevent a Blood Clot in the Lung

Unfortunately, there are too many side effects that come with this treatment. For example, I can't walk more than 15 feet without feeling dizzy and needing to sit down. Additionally, my legs and arms feel weak and I often felt like I was going to faint.

2.7

Patient Review

10/31/2022

Eliquis for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

Not long after beginning Eliquis, I started experiencing nausea. My doctors did an ablation and prescribed a new blood pressure medication; however, the side effects of the new medication were so severe that I stopped taking it within 30 minutes. I have a follow-up appointment soon, but I'm not sure what to do in the meantime.

2.3

Patient Review

6/25/2022

Eliquis for Treatment to Prevent Recurrence of a Clot in a Deep Vein

I developed an AFib after falling and injuring my knee. This required multiple surgeries, a skin graft, and a lot of physical therapy. The cost was prohibitive (90 days $420) and I could not receive help because I am on Medicare part D.

2.3

Patient Review

8/31/2022

Eliquis for Deep Vein Thrombosis Prevention

Eliquis unfortunately didn't provide the results I needed, so I had to switch back to Warfarin after 10 years.

1.7

Patient Review

5/1/2021

Eliquis for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

My mother was given this medication for Afib. A few weeks after starting the treatment, she had two strokes in quick succession. These left her bedridden and on hospice care. She also experienced bleeds from her eyes while taking this medication. I would not recommend it to anyone with Afib.

1

Patient Review

6/30/2022

Eliquis for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

My husband was prescribed this after being diagnosed with AFib around November 2020. He had a stroke at work on 6/6/22 and died 6/10/22.

1

Patient Review

9/12/2021

Eliquis for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

I think this medication is dangerous and should be taken off the market. I had no strength and all I could do was sleep. I also had hives, my lips swelled up so bad that I couldn't eat, and a minor cut on my finger took three days to stop bleeding.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about eliquis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What foods should I avoid while taking Eliquis?

"Limit caffeine intake as it can indirectly promote fatty plaques in your blood vessels and increase the risk of heart disease and stroke."

Answered by AI

Is Eliquis a blood thinner or anticoagulant?

"Eliquis is FDA-approved to help prevent and treat certain types of dangerous blood clotting that can block blood vessels throughout your body. Eliquis is an anticoagulant drug, which means it is designed to thin your blood and make it less likely to form clots."

Answered by AI

What is so special about Eliquis?

"Eliquis is a blood thinner that prevents blood clots from forming by stopping the enzyme complex called factor Xa from working. This reduces the risk of having a stroke or heart attack."

Answered by AI

What are the side effects of taking Eliquis?

"Symptoms of severe internal bleeding may include:

-bleeding from cuts that take longer to stop than usual -bleeding from the nose or gums -dizziness -easy bruising -excessively heavy menstrual bleeding -minor bleeding -nausea"

Answered by AI

What is a Eliquis used for?

"This can lead to blood clots, stroke, heart attack, and other heart problems.

Generic Name: apixaban

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots, stroke, heart attack, and other heart problems."

Answered by AI

Clinical Trials for Eliquis

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Have you considered Eliquis clinical trials?

We made a collection of clinical trials featuring Eliquis, we think they might fit your search criteria.
Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Portable Dynamic Chest X-Ray for ICU Patients

18+
All Sexes
Boston, MA

Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU. The goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care. Participants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Gyorgy Frendl, MD PhD

Have you considered Eliquis clinical trials?

We made a collection of clinical trials featuring Eliquis, we think they might fit your search criteria.
Go to Trials
Image of RUSH University Medical Center in Chicago, United States.

Thrombolysis/Thrombectomy for Deep Vein Thrombosis

18 - 75
All Sexes
Chicago, IL

The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.

Phase 4
Waitlist Available

RUSH University Medical Center

Bulent Arslan, MD

Image of Medical University of South Carolina in Charleston, United States.

Education + Decision Support for Blood Clots After Cancer Surgery

18+
All Sexes
Charleston, SC

While blood clots after major cancer surgery are common and harmful to patients, the medications to decrease blood clot risk are seldom used after patients leave the hospital despite the recommendation of multiple professional medical societies. The reason why these medications are seldom prescribed is not well understood. The main questions this study aims to answer are: * Does surgeon education paired with an electronic medical record based decision support tool improve the guideline concordant prescription of pharmacologic venous thromboembolism after abdominopelvic cancer surgery? * Does dedicated patient education regarding blood clots at the time of hospital discharge after abdominopelvic cancer surgery improve understanding of the risk of venous thromboembolism and adherence to pharmacologic prophylaxis? The investigators will study these questions using a stepped-wedge randomized trial where groups of surgeons will use a tool integrated to the electronic medical record to educate them on the individualized patient risks of blood clots after major cancer surgery and inform them regarding guidelines for preventative medicines. Utilization of the medications before and after using the tool will be compared. Patients will be administered a questionnaire assessing their awareness of blood clots as a risk after cancer surgery. For those prescribed medications to reduce blood clot risk after leaving the hospital, the questionnaire will evaluate whether they took the medications as prescribed. Survey results will be evaluated before and after implementation of education on blood clot risk at the time of hospital discharge.

Recruiting
Has No Placebo

Medical University of South Carolina

Thomas Curran, MD MPH

Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Have you considered Eliquis clinical trials?

We made a collection of clinical trials featuring Eliquis, we think they might fit your search criteria.
Go to Trials